Results 41 to 50 of about 1,397,668 (331)

Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies

open access: yesФармакоэкономика, 2018
The aim was to develop a methodology for determining the willingness to pay threshold (WTPT) and its upper limit value within the Russian health care system.Materials and methods. WTPT was calculated based on the shadow budget price (i. e.
T. S. Teptsova   +5 more
doaj   +1 more source

HIV Cure Strategies: How Good Must They Be to Improve on Current Antiretroviral Therapy? [PDF]

open access: yes, 2014
Background: We examined efficacy, toxicity, relapse, cost, and quality-of-life thresholds of hypothetical HIV cure interventions that would make them cost-effective compared to life-long antiretroviral therapy (ART).
Berkowitz, Bethany K.   +11 more
core   +19 more sources

Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer — A Decision-Analysis Model [PDF]

open access: yes, 1991
BACKGROUND. In 1988 the National Cancer Institute issued a Clinical Alert that has been widely interpreted as recommending that all women with node-negative breast cancer receive adjuvant chemotherapy.
Hillner, Bruce E., , M.D.   +1 more
core   +2 more sources

A technique for approximating transition rates from published survival analyses

open access: yesCost Effectiveness and Resource Allocation, 2019
Background Quality-adjusted-life-years (QALYs) are used to concurrently quantify morbidity and mortality within a single parameter. For this reason, QALYs can facilitate the discussion of risks and benefits during patient counseling regarding treatment ...
Markian A. Pahuta   +4 more
doaj   +1 more source

QALY losses for chronic diseases and its social distribution in the general population: results from the Belgian Health Interview Survey

open access: yesBMC Public Health, 2022
Background The burden of chronic diseases is rapidly rising, both in terms of morbidity and mortality. This burden is disproportionally carried by socially disadvantaged population subgroups.
Lisa Van Wilder   +6 more
doaj   +1 more source

El labrador: Año I Número 3 - (14/03/22) [PDF]

open access: yes, 1922
BACKGROUND: Use of everolimus-eluting stents (EES) has proven to be clinically effective and safe in patients with ST-segment elevation myocardial infarction but it remains unclear whether it is cost-effective compared to bare-metal stents (BMS) in the ...
Ademi, Zanfina   +17 more
core   +9 more sources

Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis [PDF]

open access: yes, 2016
UNLABELLED: Prisoners have a high prevalence of hepatitis C virus (HCV), but case-finding may not have been cost-effective because treatment often exceeded average prison stay combined with a lack of continuity of care. We assessed the cost-effectiveness
Brew, Iain F.   +10 more
core   +3 more sources

Economic Evaluation Plan (EEP) for A Very Early Rehabilitation Trial (AVERT): An international trial to compare the costs and cost-effectiveness of commencing out of bed standing and walking training (very early mobilization) within 24 h of stroke onset with usual stroke unit care [PDF]

open access: yes, 2016
Rationale: A key objective of A Very Early Rehabilitation Trial is to determine if the intervention, very early mobilisation following stroke, is cost-effective.
Fiona Ellery   +9 more
core   +1 more source

Measuring Quality-Adjusted Life-Years When Health Fluctuates [PDF]

open access: yesValue in Health, 2020
Recurrent fluctuations in health states can occur as a result of long-term conditions with episodic symptoms or through side effects of cycles of treatment. Fluctuations and associated duration of symptoms can be predictable (eg, side effects of chemotherapy treatment) or unpredictable (eg, relapse in multiple sclerosis). Such recurrent fluctuations in
Sanghera, Sabina, Coast, Joanna
openaire   +4 more sources

A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan

open access: yesJournal of the Formosan Medical Association, 2013
The newly available iron chelator deferasirox (Exjade, Novartis) is expected to provide better long-term clinical outcomes and improved quality of life for patients with thalassemia than its predecessor, deferoxamine (Desferal, Novartis), because of its ...
Wan-Ling Ho   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy